AIM
BMRN icon

AIA Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

AIA Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$18K Hold
235
– – ﹤0.01% 400
2020
Q2 		$29K Buy
+235
New +$23.4K 0.01% 293

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AIA Investment Management's BMRN Position: Q3 2020 in Review

AIA Investment Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2020 at 235 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #400.

AIA Investment Management first reported a position in BMRN in Q2 2020 and has held it in 2 quarters since. The position peaked at $29K in Q2 2020. 496 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

  • AIA Investment Management held 235 shares of BioMarin Pharmaceuticals worth $18K as of Q3 2020.
  • AIA Investment Management left its BioMarin Pharmaceuticals share count unchanged in Q3 2020.
  • BioMarin Pharmaceuticals made up ﹤0.01% of AIA Investment Management's portfolio in Q3 2020, its #400 holding.
  • AIA Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2020 and has held it in 2 quarters since.
  • AIA Investment Management's BioMarin Pharmaceuticals position peaked at $29K in Q2 2020.
  • 496 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on AIA Investment Management's 13F filing for Q3 2020, filed 16 Nov 2020.